Eledon Pharmaceuticals, Inc. (ELDN) analyst actions
Rating and price-target actions on ELDN in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the ELDN overview →
5 measured ELDN analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine | Press release | +0.68% | -2.19% | |
| Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions | Press release | -0.56% | -5.01% | |
| Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine | Press release | +2.17% | -0.72% | |
| Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine | Press release | +6.50% | +0.00% | |
| Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine | Press release | -0.36% | -5.03% |
Keep exploring
More ELDN: earnings → · SEC filings → · ELDN overview →